핵의학 기업 Curium, Eczacibaşi-Monrol 인수 통해 Lutetium-177 생산능력 강화와 PET 입지 확대 전망
April 09, 2024 04:13 ET
|
Curium US LLC
Eczacıbaşı-Monrol 인수 제안에 대한 내용은 다음과 같다: 이미 진행되고 있는 기존의 Lu-177 파트너십에 기반해 동위원소 제조분야의 선도적인 기업을 구축한다.현재 Curium이 진출하지 않은 지역을 대상으로 12개의 PET 사이트를 Curum의 기존 네트워크에 포함시킨다.Curium은 SPECT 제조 역량과 광범위한 물류 인프라를 추가로...
Curium 计划通过收购 Eczacibaşi-Monrol 的协议大幅扩大镥-177 产能及 PET 业务范围
April 09, 2024 04:13 ET
|
Curium US LLC
此项拟议的 Eczacıbaşı-Monrol 收购将： 在现有的镥-177 合作伙伴关系基础上，创立领先的同位素制造商在 Curium 目前没有业务的地区为其现有网络增加 12 个 PET 站点为 Curium 增加 SPECT 生产能力和广泛的物流基础设施提高诊断和治疗方案的可靠性，从而造福患者 巴黎, April 09, 2024 (GLOBE NEWSWIRE) --...
Curium plant mit der Vereinbarung zur Übernahme von Eczacıbaşı-Monrol eine erhebliche Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im PET-Bereich
April 09, 2024 04:13 ET
|
Curium
Die geplante Übernahme von Eczacıbaşı-Monrol soll Folgendes erreichen: Ausbau der bestehenden Partnerschaft im Bereich Lu-177, um führender Hersteller des Isotops zu werdenErweiterung des bestehenden...
Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol
April 08, 2024 03:25 ET
|
Curium
CURIUM AGREEMENT TO ACQUIRE ECZACIBAŞI-MONROL
CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA
March 07, 2024 08:51 ET
|
Curium
Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
March 07, 2024 08:51 ET
|
Curium
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
February 22, 2024 06:19 ET
|
Curium
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
February 06, 2024 05:23 ET
|
Curium
Exciting news from Curium! Starting April 5, 2024, our Ioflupane I 123 Injection will be delivered Monday through Friday.
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
November 23, 2023 07:47 ET
|
Curium
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
November 16, 2023 05:14 ET
|
Curium
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...